Corona depletion is felt everywhere, worries dominate everyday life – the craving for a vaccine grows stronger and stronger. A word from Health Minister Jens Spahn (CDU) in this direction may, meanwhile, become relevant to the stock market. This shows that his ministry on Friday is struggling to capture a “photo” report. In a video link from the health minister, Spahn said the Mainz-based company Biontech was about to approve a vaccine. When asked when he expected the first vaccinations, Spahn said, “That could happen before the end of the year.”
His spokesperson emphasizes about the report: internal discussions are usually not commented on. Coincidence or not: the price of the Biontech share sometimes rose by about 5 percent to 77.70 euros. Spahn, currently infected with the coronavirus himself, and his husband, will officially continue to see a vaccine in early 2021 as the more realistic scenario. He and Research Minister Anja Karliczek (CDU) expect vaccinations to begin in the first quarter of 2021. To start the vaccination immediately, the ministry has now asked state governments to provide delivery addresses for the vaccine and thus the locations by Nov. 10. for vaccination centers.
Nationally, 60 large vaccination centers are planned, the number of delivery and storage locations per state depends on the size of the population, the so-called Königsteiner key. Government circles in Lower Saxony say they were asked to name five delivery stations. Spahn, for example, can imagine the main vaccination centers in exhibition halls. The vaccines should be transported and stored at temperatures down to -70 degrees. Suitable equipment is needed for this, especially since the substances would have to come in very large quantities. Berlin wants to distribute the vaccine from the storage location in such a way that it can be administered in at least 15 vaccination centers
Vaccinate all citizens in 6.7 months
The minister now told Spiegel it could be in January, maybe February or March – or even later. “Of course it would be best if a vaccine prevented new infections. But it would also be beneficial if it made the course of the disease milder, ”said Spahn. Once there is enough vaccine, “in six or seven months will a large number of those who want to get vaccinated”. Obviously, nurses, doctors and medical professionals need to be vaccinated first.
He categorically refuses to be vaccinated and does not understand why he keeps asking for it and has to clarify it for the umpteenth time. In addition, he promises that thanks to the concluded preliminary contracts there will be enough material for anyone who wants to be vaccinated: “We will receive much more vaccine than we will need”. What is left can still be sold to other countries or given to poor countries. “
[Wenn Sie die wichtigsten News aus Berlin, Deutschland und der Welt live auf Ihr Handy haben wollen, empfehlen wir Ihnen unsere runderneuerte App, die Sie hier für Apple- und Android-Geräte herunterladen können.]
German companies such as Biontech and Curevac are also at the forefront of the race for the corona vaccine Photo: dpa
SPD health expert Karl Lauterbach emphasized at a digital conference of the SPD Economic Forum that the likelihood of a good effect with justified side effects is high: “Nearly 200 vaccines against the coronavirus are currently being developed. Science has never worked together so strongly or so quickly on an infection. “The industry is concerned that production and filling capacity will also have to be expanded rapidly in Germany.
Who will win?
Some vaccine developments are now in pivotal phase 3 studies. CoronaVac from Chinese company Sinovac Biotech is currently being tested with tens of thousands of volunteers in Brazil, Turkey and Indonesia. In China, CoronaVac was already approved in late August to vaccinate high-risk groups, especially health workers, for emergencies.
The Pfizer duo and Mainz-based company Biontech are also in a phase 3 study involving 44,000 volunteers in South America – hoping for an emergency permit in the US by December.
Since the end of July, mRNA-1273, a vaccine from the American company Moderna, has also been in the phase 3 clinical trial. Moderna is also hoping for US emergency clearance this year. The Tübingen-based company Curevac has been testing its vaccine candidate on hundreds of subjects in Peru and Panama since the end of September, but is “only” in a phase 2 study.
[Jeden Morgen informieren wir Sie, liebe Leserinnen und Leser, in unserer Morgenlage über die politischen Entscheidungen, Nachrichten und Hintergründe. Zur kostenlosen Anmeldung geht es hier.]
There should be no compulsory vaccination – even if the opponents of Minister Spahn continue to believe Photo: epd
A setback was reported this week in the development of the AZD1222 vaccine, which the British-Swedish company AstraZeneca and the University of Oxford are working on: a subject who reportedly received a placebo and not the vaccine is in the study, which is performed in Brazil. is executed, died.
In fact, massive vaccinations against the coronavirus are expected to start in Moscow between December and January. The first major shipments of the first Russian vaccine were expected to arrive next month, Mayor Sergei Sobyanin said. “This will be the ultimate victory over the pandemic,” said Sobjanin. The Russian vaccine called “SputnikV” was already released in August. There has been international criticism because approval was given before the completion of major tests.
Steinmeier sees global character test
But the bottom line is that, at least in this area, hope prevails: in early April, Federal President Frank-Walter Steinmeier had announced in the Financial Times a worldwide alliance with the King of Jordan, the Presidents of Singapore and Ethiopia and president of Ecuador. “Human experience tells us that almost all epidemics that have claimed human lives – tuberculosis, smallpox, Ebola, AIDS – have been overcome by modern medicine, which has succeeded in developing therapies and vaccines,” the heads of state wrote at the time.
And they stressed that this was a global character test, that the crisis could be an opportunity. Her hope to this day: the internationalization of vaccine development, production and distribution will provide the antidote not only to the virus itself, “but also to the political upheavals that have intensified since its outbreak.”